127 related articles for article (PubMed ID: 28981526)
1. Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.
Robles-Fernandez I; Martinez-Gonzalez LJ; Pascual-Geler M; Cozar JM; Puche-Sanz I; Serrano MJ; Lorente JA; Alvarez-Cubero MJ
PLoS One; 2017; 12(10):e0185447. PubMed ID: 28981526
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
Lévesque É; Huang SP; Audet-Walsh É; Lacombe L; Bao BY; Fradet Y; Laverdière I; Rouleau M; Huang CY; Yu CC; Caron P; Guillemette C
Clin Cancer Res; 2013 Feb; 19(3):699-709. PubMed ID: 23186779
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
Yamada T; Nakayama M; Shimizu T; Nonen S; Nakai Y; Nishimura K; Fujio Y; Okuyama A; Azuma J; Nonomura N
Int J Clin Oncol; 2013 Aug; 18(4):711-7. PubMed ID: 22714708
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
Gu C; Li Q; Zhu Y; Qu Y; Zhang G; Wang M; Yang Y; Wang J; Jin L; Wei Q; Ye D
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):310-6. PubMed ID: 26238235
[TBL] [Abstract][Full Text] [Related]
5. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
6. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.
Xie W; Yang M; Chan J; Sun T; Mucci LA; Penney KL; Lee GS; Kantoff PW
Prostate; 2016 May; 76(7):691-9. PubMed ID: 26847995
[TBL] [Abstract][Full Text] [Related]
8. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.
Severi G; Hayes VM; Tesoriero AA; Southey MC; Hoang HN; Padilla EJ; Morris HA; English DR; Sutherland RL; Boyle P; Hopper JL; Giles GG
BJU Int; 2008 Feb; 101(4):492-6. PubMed ID: 17986287
[TBL] [Abstract][Full Text] [Related]
9. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.
Sun T; Oh WK; Jacobus S; Regan M; Pomerantz M; Freedman ML; Lee GS; Kantoff PW
Cancer Prev Res (Phila); 2011 Dec; 4(12):2044-50. PubMed ID: 21900597
[TBL] [Abstract][Full Text] [Related]
10. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP; Ting WC; Chen LM; Huang LC; Liu CC; Chen CW; Hsieh CJ; Yang WH; Chang TY; Lee HZ; Bao BY
Ann Surg Oncol; 2010 Jan; 17(1):312-22. PubMed ID: 19777185
[TBL] [Abstract][Full Text] [Related]
11. Associations between estrogen receptor genetic polymorphisms, smoking status, and prostate cancer risk: a case-control study in Japanese men.
Lu X; Yamano Y; Takahashi H; Koda M; Fujiwara Y; Hisada A; Miyazaki W; Katoh T
Environ Health Prev Med; 2015 Sep; 20(5):332-7. PubMed ID: 26251204
[TBL] [Abstract][Full Text] [Related]
12. Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):28-34. PubMed ID: 26754263
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
14. Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy.
Chang CF; Pao JB; Yu CC; Huang CY; Huang SP; Yang YP; Huang CN; Chang TY; You BJ; Lee HZ; Hour TC; Bao BY
Ann Surg Oncol; 2013 Jul; 20(7):2446-52. PubMed ID: 23397154
[TBL] [Abstract][Full Text] [Related]
15. Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.
Cornu JN; Audet-Walsh E; Drouin S; Bigot P; Valeri A; Fournier G; Azzouzi AR; Roupret M; Cormier L; Chanock S; Guillemette C; Cussenot O; Lévesque E; Cancel-Tassin G
World J Urol; 2017 Feb; 35(2):293-298. PubMed ID: 27277477
[TBL] [Abstract][Full Text] [Related]
16. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
17. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
18. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor polymorphisms and the risk of endometrial cancer.
Ashton KA; Proietto A; Otton G; Symonds I; McEvoy M; Attia J; Gilbert M; Hamann U; Scott RJ
BJOG; 2009 Jul; 116(8):1053-61. PubMed ID: 19438492
[TBL] [Abstract][Full Text] [Related]
20. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
